<DOC>
	<DOCNO>NCT01702298</DOCNO>
	<brief_summary>The purpose study examine safety tolerability sitagliptin 100 mg/simvastatin 40 mg FDC ( MK-0431D ) Vietnamese participant type 2 diabetes mellitus inadequate glycemic control metformin .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability Sitagliptin/Simvastatin Fixed-dose Combination ( FDC ) Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control Metformin Monotherapy ( MK-0431D-312 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Has type 2 diabetes mellitus Male , female reproductive potential reproductive potential agrees abstain use ( partner use ) two acceptable method birth control study 14 day last dose study drug Currently metformin monotherapy ( &gt; =1000 mg per day ) least 4 week prior study participation Not statin therapy lipidlowering agent least 6 week prior study participation History type 1 diabetes mellitus history ketoacidosis History 2 episode hypoglycemia result seizure , coma loss consciousness past 3 month On thiazolidinedione ( TZD ) within past 12 week Has treat statin lipidlowering agent within 6 week prior study participation Is likely require treatment prohibit medication ( itraconazole , ketoconazole , posaconazole , erythromycin , clarithromycin , telithromycin , HIV protease inhibitor , nefazodone , gemfibrozil , cyclosporine , danazol , amiodarone , verapamil , diltiazem , amlodipine , ranolazine , niacin ) Intends consume &gt; 1.2 liter grapefruit juice per day study Is likely require treatment &gt; =2 consecutive week repeat course corticosteroid ( inhale , nasal topical corticosteroid permit ) Is weight loss program maintenance phase start weight loss medication undergone bariatric surgery within 12 month prior study participation Has undergone surgical procedure within 4 week study participation plan major surgery study History myopathy rhabdomyolysis statin History myocardial infarction , unstable stable angina , angioplasty , bypass surgery , myocardial ischemia , peripheral artery disease , abdominal aortic aneurysm , transient ischemic attack , stroke carotid origin &gt; 50 % obstruction carotid artery Diagnosis congestive heart failure New York Heart Association ( NYHA ) Class III IV cardiac status History active liver disease ( nonalcoholic steatosis ) include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Chronic progressive neuromuscular disorder Human immunodeficiency virus ( HIV ) Hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Currently treat hyperthyroidism thyroid hormone replacement therapy stable dose least 6 week History malignancy &lt; =5 year prior study participation , except basal cell squamous cell skin cancer situ cervical cancer Positive urine pregnancy test Pregnant breastfeeding , expect conceive donate egg study , include 14 day follow last dose study drug User recreational illicit drug recent history drug abuse Routinely consume &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week , engage binge drinking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>